MARKET

BCAB

BCAB

Bioatla, Inc.
NASDAQ
0.5580
+0.0609
+12.25%
After Hours: 0.5382 -0.0198 -3.55% 18:56 05/02 EDT
OPEN
0.4903
PREV CLOSE
0.4971
HIGH
0.5751
LOW
0.4903
VOLUME
1.30M
TURNOVER
--
52 WEEK HIGH
3.530
52 WEEK LOW
0.2400
MARKET CAP
32.60M
P/E (TTM)
-0.3884
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCAB last week (0421-0425)?
Weekly Report · 5d ago
BioAtla announces poster presentations at 2025 AACR meeting
TipRanks · 04/24 12:16
BIOATLA ANNOUNCES POSTER PRESENTATIONS AT THE 2025 AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR) ANNUAL MEETING
Reuters · 04/24 12:00
BioAtla's Phase 2 Trial Of Ozuriftamab Vedotin Selected For Poster Presentation at 2025 ASCO
Benzinga · 04/23 14:09
BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Barchart · 04/23 09:05
Weekly Report: what happened at BCAB last week (0414-0418)?
Weekly Report · 04/21 10:41
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 04/14 21:06
Weekly Report: what happened at BCAB last week (0407-0411)?
Weekly Report · 04/14 10:34
More
About BCAB
More
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Recently
Symbol
Price
%Change

Webull offers Bioatla Inc stock information, including NASDAQ: BCAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCAB stock methods without spending real money on the virtual paper trading platform.